Evidence map›Paper›PMID 42177263›Full record

ArticleScientific reports2026

BCG immunisation through intranasal instillation protects mice against Streptococcus pneumoniae infection by enhancing alveolar macrophage activity.

Valentin Sencio, Camille Bouzet, Joan Fine, Charlotte Costa, Axelle Grandé, Alexandre Vandeputte, Laurye Van Maele, Carine Rouanet, Jean-Claude Sirard, Arnaud Machelart

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valentin SencioUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France. valentin.sencio@cnrs.fr.
Camille BouzetUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Joan FineUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Charlotte CostaUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Axelle GrandéUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Alexandre VandeputteUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Laurye Van MaeleUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Carine RouanetUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Jean-Claude SirardUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Arnaud MachelartUniv. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France. arnaud.machelart@inserm.fr.

Funding

Agence Nationale de la Recherche ANR-18-JAM2-0002 and ANR-22-CE18-0021-01ANRS-MIE No. ANRS0521European Fund for Regional Economic Development HDF 003447Innovative Medicines Initiative 2 Joint Undertaking No. 853989 (ERA4TB)Région Hauts-de-France DOS0190627/00 - Start-AIRR BPI Program
6 · The paper itself

Abstract

Pneumonia remains a leading cause of morbidity and mortality worldwide, especially among young children, the elderly, and immunocompromised individuals. Streptococcus pneumoniae is the most common bacterial cause of community-acquired pneumonia, and the rise of antimicrobial resistance highlights the urgent need for innovative approaches to strengthen host defences. The Bacille Calmette-Guérin (BCG) vaccine, originally developed to prevent tuberculosis, has been shown to provide heterologous protection against unrelated pathogens, mediated by diverse innate and adaptive immune mechanisms. Furthermore, as mucosal delivery has recently been shown to induce stronger local immune responses, intranasal administration of BCG emerges as a promising strategy against S. pneumoniae infection. Here, we investigated the protective effects of BCG immunisation through intranasal instillation in a murine model of S. pneumoniae infection, in comparison with the classical subcutaneous route. Intranasal BCG administration markedly reduced pneumococcal burden and improved mice survival up to three months post-immunisation. This protection was associated with a dampened inflammatory cytokine response while preserving efficient bacterial clearance. Mechanistically, alveolar macrophages were identified as key mediators of protection, as their depletion abolished the beneficial effect of BCG intranasal instillation. In vitro, BCG stimulation enhanced the phagocytic and bactericidal activities of macrophages against S. pneumoniae, which may explain the clearance of the bacteria observed in vivo in immunised mice. In summary, our study demonstrates that BCG immunisation, through intranasal instillation, provides transient heterologous protection against S. pneumoniae by activating alveolar macrophages. These findings highlight intranasal BCG administration as a promising approach to enhance local lung immunity and reduce susceptibility to bacterial pneumonia.

Indexed as

BCG VaccineMacrophages, AlveolarPneumococcal InfectionsStreptococcus pneumoniaeAdministration, IntranasalAnimalsCytokinesDisease Models, AnimalFemaleMiceMice, Inbred C57BLPhagocytosisBCG VaccineCytokinesAlveolar macrophagesBCGHeterologous immunityIntranasal instillationMucosal immunityStreptococcus pneumoniae

Identifiers

PMID42177263
PMCPMC13542153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.